Creel, García-Céullar, Aiza y Enríquez is the largest Mexican firm in the GCR 100, and a new entry this year. Its competition practice comprises two partners and three associates, and is led by Who's Who nominee Luis Gerardo Garcia and Jose Ruiz.
|Creel, García-Céullar, Aiza y Enríquez|| |
|Global heads: Luis Gerardo Garcia and Jose Ruiz|
|Home jurisdiction: Mexico|
|Total size of firm: 110|
|No. of competition lawyers: 7|
|% of firm specialised: 6|
|Who’s Who nominees: 1|
|Equity partners: 2|
|No. of lateral partner hires: 0|
|No. of partner departures: 0|
|No. of internal promotions: 0|
On the merger front, the firm acted for a variety of local and international clients this year. For example, it represented US wine and spirit company Brown-Forman in its contested acquisition of Mexican tequila producer Casa Herradura, and US private equity firm Ripplewood Holdings in its multi-jurisdictional acquisition of the Reader's Digest Association.
Creel advised two US natural gas compression unit companies with a significant presence in Mexico, in connection with a merger. It also represented automotive engineering company Cadence Innovation on the potential acquisition of the plastic and cockpit systems division of Collins & Aikman Corporation.
Creel worked on a host of automobile-related deals this year, including Porsche's mandatory tender offer to acquire Volkswagen, and Thornwood Associates's acquisition of US automotive products supplier Federal-Mogul Corporation. It acted for private investment firm Cerberus in two separate acquisitions – one of car manufacturer Chrysler, the other of US car-frame producer Tower Automotive.
It also advised American Real Estate Partners on its potential acquisition of car-interiors manufacturer Lear Corporation, and FIM Holdings, a consortium formed by Cerberus, Citigroup, Aozora Bank and PNC Investment Corp, on its acquisition of a majority sharehold in General Motors Acceptance Corporation.
On the litigation front, the firm represented a large pharmaceutical company in a cartel investigation by the Mexican Competition Commission that probed the sale of medication to the public sector.